A Chinese research team has made significant advancements in the treatment of colorectal cancer, paving the way for a new milestone in the field of oncology treatment

A Chinese research team has made significant advancements in the treatment of colorectal cancer, paving the way for a new milestone in the field of oncology treatment

In recent years, natural killer (NK) cell immunotherapy has gained significant attention as a promising approach for treating solid tumors and malignant tumors of the blood system. NK cells, constituting 5% to 15% of lymphocyte circulation, are regarded as natural warriors against cancer, capable of directly identifying and killing cancer cells.

Umbilical cord blood NK cells bring new treatment options for colorectal cancer patients!

In a paper published in the journal “Human Gene Therapy” by a Chinese research team, researchers successfully expanded NK cells from umbilical cord blood (UCB) by utilizing membrane-bound interleukin (IL)-21, naming them eUCB-NK cells. Animal experiments demonstrated the robust in vivo anti-tumor activity of umbilical cord blood NK cells, suitable for late-stage colorectal cancer patients. Combining with bevacizumab can enhance NK cell infiltration, leading to improved therapeutic outcomes.

Moreover, CAR-NK therapy holds considerable promise. By genetically engineering chimeric antibodies into NK cells, they become capable of recognizing and destroying tumor cells. Safety and efficacy have been demonstrated in the treatment of colorectal cancer.

A study focusing on metastatic colorectal cancer revealed that local infusion of NKG2D mRNA CAR-NK cells led to rapid tumor reduction in patients, with no significant adverse events observed during the treatment process, introducing a novel strategy for tumor immunotherapy.

#ColorectalCancerTreatment #CancerResearch #NKCellTherapy #MedicalBreakthroughs #CancerTreatmentAdvances #TumorImmunotherapy #HealthInnovation #ScienceNews #OncologyProgress #eUCBNKCells